ImmunityBio, Inc. (IBRX)
$9.91+1.12%Close
BUYRECOVERY · day 48
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV37.5%–194.0%
- Market cap
- $10.4B
- Beta
- 0.13
- P/E (TTM)
- -10.18
- IV-%ile
- 65
- IV ATM
- 105.7%
- Short % float
- 109.01%
- Days to cover
- 8.9
- SI change
- -1.1%
- 1W
- +1.64%
- 1M
- +21.74%
- vs SPY 1W
- +2.62%
- vs SPY 1M
- +19.88%
Industry peers
FMP comparable companies · ranked by market cap
- MRNABUYModerna, Inc.$85.8BRECOVERYQ 36$216.25+4.65%
- BNTXSELLBioNTech SE$22.4BCRISISQ 35$89.01-0.39%
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 8$14.50-2.00%
- LEGNSELLLegend Biotech Corporation$3.3BRECOVERYQ 3$17.88+6.49%
- VIRBUYVir Biotechnology, Inc.$1.8BRECOVERYQ 12$10.61-1.89%
- IMCRSELLImmunocore Holdings plc$1.4BBEARQ 1$27.82+1.87%
- IMTXSELLImmatics N.V.$916MCRISISQ 5$6.83+2.49%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 9
- GROWTH
- 11
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC81.0%
REV YoY-
ROE135.0%
EPS YoY-
ROA-157.9%
GROSS95
OP-152
NET-599
[VALUATION]
P/E TTM-10.18
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-9.94
P/FCF-
EV/EBITDA-12.59
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO5.72
ND/EBITDA-
BETA0.13
Company news
FAQ
- What is LOPJLB’s current signal on IBRX?
- LOPJLB’s latest quantitative signal on ImmunityBio, Inc. (IBRX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is IBRX in?
- ImmunityBio, Inc. (IBRX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does ImmunityBio, Inc. (IBRX) do?
- ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel an…